{
  "trial_id": "NCT04114630",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Signed informed consent must be obtained prior to participation in the study.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Adults \u226518 years of age upon entry into screening.",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "Patient diagnosed with chronic and high -frequency episodic migraine (with or without aura) for at least 1 year prior to screening according to the International Classification of Headache Disorders-3rd Edition (ICHD-3).",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Patient with a documented diagnosis in clinical history of one or more of the following comorbidities: chronic fatigue, fibromyalgia and/or IBS.",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Patients previously treated with other monoclonal antibodies for migraine can be included if the appropriate washout period according to product half-life has been done for each monoclonal antibody.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Migraine frequency of \u2265 10 migraine days during the Baseline Epoch, confirmed by the eDiary.",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "\u2265 80% eDiary compliance during the Baseline Epoch.",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "exclusion": [
    {
      "criterion": "Older than 50 years of age at migraine onset.",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "Unable to differentiate migraine from other headaches.",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "History of cluster headache or hemiplegic migraine headache.",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "Used a device, or procedure within 2 months prior to the start of or during baseline or during the treatment period.",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Use of other investigational drugs within 5 half-lives of enrollment or inappropriate washout period in case of monoclonal antibodies, or until the expected pharmacodynamic effect has returned to baseline, whichever is longer.",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "Unlikely to be able to complete all protocol required study visits or procedures, and/or to comply with all required study procedures.",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "History or evidence of any other unstable or clinically significant medical condition that in the opinion of the investigator would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.",
      "label": "not_met",
      "evidence": "unknown"
    }
  ],
  "notes": "The patient is a 15 year old girl with recurrent bilateral headache. She has been diagnosed with migraine and is under treatment.",
  "_meta": {
    "topic_id": "35",
    "trial_id": "NCT04114630",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}